![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
Vol. 12, Issue 4, 863-879, April 2001
Rochelle Belfer Chemotherapy Foundation Laboratory, Division of
Medical Oncology, Department of Medicine, Mount Sinai School of
Medicine, New York, New York 10029
We discovered that a shift between the state of
tumorigenicity and dormancy in human carcinoma (HEp3) is attained
through regulation of the balance between two classical
mitogen-activated protein kinase (MAPK)-signaling pathways, the
mitogenic extracellular regulated kinase (ERK) and the apoptotic/growth
suppressive stress-activated protein kinase 2 (p38MAPK), and that urokinase plasminogen activator
receptor (uPAR) is an important regulator of these events. This is a
novel function for uPAR whereby, when expressed at high level, it
enters into frequent, activating interactions with the
5
1-integrin, which facilitates the formation of insoluble
fibronectin (FN) fibrils. Activation of 51-integrin by
uPAR generates persistently high level of active ERK necessary for
tumor growth in vivo. Our results show that ERK
activation is generated through a convergence of two pathways: a
positive signal through uPAR-activated 51, which activates ERK,
and a signal generated by the presence of FN fibrils that suppresses
p38 activity. When fibrils are removed or their assembly is blocked,
p38 activity increases. Low uPAR derivatives of HEp3 cells, which are
growth arrested (dormant) in vivo, have a high p38/ERK activity ratio,
but in spite of a similar level of 51-integrin, they do
not assemble FN fibrils. However, when p38 activity is inhibited by
pharmacological (SB203580) or genetic (dominant negative-p38)
approaches, their ERK becomes activated, uPAR is overexpressed,
51-integrins are activated, and dormancy is interrupted.
Restoration of these properties in dormant cells can be mimicked by a
direct re-expression of uPAR through transfection with a uPAR-coding
plasmid. We conclude that overexpression of uPAR and its interaction
with the integrin are responsible for generating two feedback
loops; one increases the ERK activity that feeds back by increasing the
expression of uPAR. The second loop, through the presence of FN
fibrils, suppresses p38 activity, further increasing ERK activity.
Together these results indicate that uPAR and its interaction with the
integrin should be considered important targets for induction
of tumor dormancy.
This article has been cited by other articles:
|
|
 |
|
  A. P. Adam, A. George, D. Schewe, P. Bragado, B. V. Iglesias, A. C. Ranganathan, A. Kourtidis, D. S. Conklin, and J. A. Aguirre-Ghiso Computational Identification of a p38SAPK-Regulated Transcription Factor Network Required for Tumor Cell Quiescence Cancer Res., July 15, 2009; 69(14): 5664 - 5672. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Hildenbrand, M. Niedergethmann, A. Marx, D. Belharazem, H. Allgayer, C. Schleger, and P. Strobel Amplification of the Urokinase-Type Plasminogen Activator Receptor (uPAR) Gene in Ductal Pancreatic Carcinomas Identifies a Clinically High-Risk Group Am. J. Pathol., June 1, 2009; 174(6): 2246 - 2253. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Monaghan-Benson, C. C. Mastick, and P. J. McKeown-Longo A dual role for caveolin-1 in the regulation of fibronectin matrix assembly by uPAR J. Cell Sci., November 15, 2008; 121(22): 3693 - 3703. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Schewe and J. A. Aguirre-Ghiso ATF6{alpha}-Rheb-mTOR signaling promotes survival of dormant tumor cells in vivo PNAS, July 29, 2008; 105(30): 10519 - 10524. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Vial and P. J. McKeown-Longo PAI1 stimulates assembly of the fibronectin matrix in osteosarcoma cells through crosstalk between the {alpha}v{beta}5 and {alpha}5{beta}1 integrins J. Cell Sci., May 15, 2008; 121(10): 1661 - 1670. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wei, C.-H. Tang, Y. Kim, L. Robillard, F. Zhang, M. C. Kugler, and H. A. Chapman Urokinase Receptors Are Required for {alpha}5beta1 Integrin-mediated Signaling in Tumor Cells J. Biol. Chem., February 9, 2007; 282(6): 3929 - 3939. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Yang, H. Avila, H. Wang, J. Trevino, G. E. Gallick, Y. Kitadai, T. Sasaki, and D. D. Boyd Plasticity in Urokinase-Type Plasminogen Activator Receptor (uPAR) Display in Colon Cancer Yields Metastable Subpopulations Oscillating in Cell Surface uPAR Density--Implications in Tumor Progression Cancer Res., August 15, 2006; 66(16): 7957 - 7967. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Franco, I. Vocca, M. V. Carriero, D. Alfano, L. Cito, I. Longanesi-Cattani, P. Grieco, L. Ossowski, and M. P. Stoppelli Activation of urokinase receptor by a novel interaction between the connecting peptide region of urokinase and {alpha}v{beta}5 integrin J. Cell Sci., August 15, 2006; 119(16): 3424 - 3434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chaurasia, J. A. Aguirre-Ghiso, O. D. Liang, H. Gardsvoll, M. Ploug, and L. Ossowski A Region in Urokinase Plasminogen Receptor Domain III Controlling a Functional Association with {alpha}5beta1 Integrin and Tumor Growth J. Biol. Chem., May 26, 2006; 281(21): 14852 - 14863. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Monaghan-Benson and P. J. McKeown-Longo Urokinase-type Plasminogen Activator Receptor Regulates a Novel Pathway of Fibronectin Matrix Assembly Requiring Src-dependent Transactivation of Epidermal Growth Factor Receptor J. Biol. Chem., April 7, 2006; 281(14): 9450 - 9459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Spangenberg, E. U. Lausch, T. M. Trost, D. Prawitt, A. May, R. Keppler, S. A. Fees, D. Reutzel, C. Bell, S. Schmitt, et al. ERBB2-Mediated Transcriptional Up-regulation of the {alpha}5{beta}1 Integrin Fibronectin Receptor Promotes Tumor Cell Survival Under Adverse Conditions. Cancer Res., April 1, 2006; 66(7): 3715 - 3725. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Naumov, E. Bender, D. Zurakowski, S.-Y. Kang, D. Sampson, E. Flynn, R. S. Watnick, O. Straume, L. A. Akslen, J. Folkman, et al. A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype. J Natl Cancer Inst, March 1, 2006; 98(5): 316 - 325. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Hickson, D. Huo, D. J. Vander Griend, A. Lin, C. W. Rinker-Schaeffer, and S. D. Yamada The p38 Kinases MKK4 and MKK6 Suppress Metastatic Colonization in Human Ovarian Carcinoma Cancer Res., February 15, 2006; 66(4): 2264 - 2270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C. Ranganathan, L. Zhang, A. P. Adam, and J. A. Aguirre-Ghiso Functional Coupling of p38-Induced Up-regulation of BiP and Activation of RNA-Dependent Protein Kinase-Like Endoplasmic Reticulum Kinase to Drug Resistance of Dormant Carcinoma Cells Cancer Res., February 1, 2006; 66(3): 1702 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Zhang, R. S. Mitra, B. S. Henson, N. S. Datta, L. K. McCauley, P. Kumar, J. S.-J. Lee, T. E. Carey, and N. J. D'Silva Rap1GAP Inhibits Tumor Growth in Oropharyngeal Squamous Cell Carcinoma Am. J. Pathol., February 1, 2006; 168(2): 585 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Mazzieri, S. D'Alessio, R. K. Kenmoe, L. Ossowski, and F. Blasi An Uncleavable uPAR Mutant Allows Dissection of Signaling Pathways in uPA-dependent Cell Migration Mol. Biol. Cell, January 1, 2006; 17(1): 367 - 378. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Boukerche, Z.-z. Su, L. Emdad, P. Baril, B. Balme, L. Thomas, A. Randolph, K. Valerie, D. Sarkar, and P. B. Fisher mda-9/Syntenin: A Positive Regulator of Melanoma Metastasis Cancer Res., December 1, 2005; 65(23): 10901 - 10911. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. J. Vander Griend, M. Kocherginsky, J. A. Hickson, W. M. Stadler, A. Lin, and C. W. Rinker-Schaeffer Suppression of Metastatic Colonization by the Context-Dependent Activation of the c-Jun NH2-Terminal Kinase Kinases JNKK1/MKK4 and MKK7 Cancer Res., December 1, 2005; 65(23): 10984 - 10991. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Gargiulo, I. Longanesi-Cattani, K. Bifulco, P. Franco, R. Raiola, P. Campiglia, P. Grieco, G. Peluso, M. P. Stoppelli, and M. V. Carriero Cross-talk between fMLP and Vitronectin Receptors Triggered by Urokinase Receptor-derived SRSRY Peptide J. Biol. Chem., July 1, 2005; 280(26): 25225 - 25232. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jo, K. S. Thomas, N. Marozkina, T. J. Amin, C. M. Silva, S. J. Parsons, and S. L. Gonias Dynamic Assembly of the Urokinase-type Plasminogen Activator Signaling Receptor Complex Determines the Mitogenic Activity of Urokinase-type Plasminogen Activator J. Biol. Chem., April 29, 2005; 280(17): 17449 - 17457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bass, F. Werner, E. Odintsova, T. Sugiura, F. Berditchevski, and V. Ellis Regulation of Urokinase Receptor Proteolytic Function by the Tetraspanin CD82 J. Biol. Chem., April 15, 2005; 280(15): 14811 - 14818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Wei, R.-P. Czekay, L. Robillard, M. C. Kugler, F. Zhang, K. K. Kim, J.-p. Xiong, M. J. Humphries, and H. A. Chapman Regulation of {alpha}5{beta}1 integrin conformation and function by urokinase receptor binding J. Cell Biol., January 31, 2005; 168(3): 501 - 511. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Meng, D. Tripathy, E. P. Frenkel, S. Shete, E. Z. Naftalis, J. F. Huth, P. D. Beitsch, M. Leitch, S. Hoover, D. Euhus, et al. Circulating Tumor Cells in Patients with Breast Cancer Dormancy Clin. Cancer Res., December 15, 2004; 10(24): 8152 - 8162. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Aguirre-Ghiso, L. Ossowski, and S. K. Rosenbaum Green Fluorescent Protein Tagging of Extracellular Signal-Regulated Kinase and p38 Pathways Reveals Novel Dynamics of Pathway Activation during Primary and Metastatic Growth Cancer Res., October 15, 2004; 64(20): 7336 - 7345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. E. Spaner Amplifying cancer vaccine responses by modifying pathogenic gene programs in tumor cells J. Leukoc. Biol., August 1, 2004; 76(2): 338 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Zhang, X. Cai, J. M. Lopez-Guisa, S. J. Collins, and A. A. Eddy Mitogenic Signaling of Urokinase Receptor-Deficient Kidney Fibroblasts: Actions of an Alternative Urokinase Receptor and LDL Receptor-Related Protein J. Am. Soc. Nephrol., August 1, 2004; 15(8): 2090 - 2102. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Korah, M. Boots, and R. Wieder Integrin {alpha}5{beta}1 Promotes Survival of Growth-Arrested Breast Cancer Cells: An in Vitro Paradigm for Breast Cancer Dormancy in Bone Marrow Cancer Res., July 1, 2004; 64(13): 4514 - 4522. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Liu and P. A. Hofmann Protein phosphatase 2A-mediated cross-talk between p38 MAPK and ERK in apoptosis of cardiac myocytes Am J Physiol Heart Circ Physiol, June 1, 2004; 286(6): H2204 - H2212. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, L. Yang, Md. S. Jamaluddin, and D. D. Boyd The Kruppel-like KLF4 Transcription Factor, a Novel Regulator of Urokinase Receptor Expression, Drives Synthesis of This Binding Site in Colonic Crypt Luminal Surface Epithelial Cells J. Biol. Chem., May 21, 2004; 279(21): 22674 - 22683. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Liu, S. Yin, N. Reddy, C. Spencer, and S. Sheng Bax Mediates the Apoptosis-Sensitizing Effect of Maspin Cancer Res., March 1, 2004; 64(5): 1703 - 1711. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Ossowski, J. Aguirre Ghiso, D. Liu, Y. Estrada, and S. Rosenbaum The role of ERK and p38 in regulation of tumor dormancy. AACR Meeting Abstracts, March 1, 2004; 2004(1): 1318 - 1319. [Abstract]
|
|
|
|
|
|
D. D. Boyd, H. Wang, H. Avila, N. U. Parikh, H. Kessler, V. Magdolen, and G. E. Gallick Combination of an Src Kinase Inhibitor with a Novel Pharmacological Antagonist of the Urokinase Receptor Diminishes in Vitro Colon Cancer Invasiveness Clin. Cancer Res., February 15, 2004; 10(4): 1545 - 1555. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Monaghan, V. Gueorguiev, C. Wilkins-Port, and P. J. McKeown-Longo The Receptor for Urokinase-type Plasminogen Activator Regulates Fibronectin Matrix Assembly in Human Skin Fibroblasts J. Biol. Chem., January 9, 2004; 279(2): 1400 - 1407. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Klein, M. Zheng, A. Ambesi, L. Van De Water, and P. J. McKeown-Longo Stimulation of extracellular matrix remodeling by the first type III repeat in fibronectin J. Cell Sci., November 15, 2003; 116(22): 4663 - 4674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mazzoni, A. Adam, E. Bal de Kier Joffe, and J. A. Aguirre-Ghiso Immortalized Mammary Epithelial Cells Overexpressing Protein Kinase C {gamma} Acquire a Malignant Phenotype and Become Tumorigenic in Vivo Mol. Cancer Res., August 1, 2003; 1(10): 776 - 787. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Aguirre-Ghiso, Y. Estrada, D. Liu, and L. Ossowski ERKMAPK Activity as a Determinant of Tumor Growth and Dormancy; Regulation by p38SAPK Cancer Res., April 1, 2003; 63(7): 1684 - 1695. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. D. Boyd, S.-J. Kim, H. Wang, T. R. Jones, and G. E. Gallick A Urokinase-Derived Peptide (A6) Increases Survival of Mice Bearing Orthotopically Grown Prostate Cancer and Reduces Lymph Node Metastasis Am. J. Pathol., February 1, 2003; 162(2): 619 - 626. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Zijlstra, R. Mellor, G. Panzarella, R. T. Aimes, J. D. Hooper, N. D. Marchenko, and J. P. Quigley A Quantitative Analysis of Rate-limiting Steps in the Metastatic Cascade Using Human-specific Real-Time Polymerase Chain Reaction Cancer Res., December 1, 2002; 62(23): 7083 - 7092. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Bass, A.-M. M. Fernandez, and V. Ellis Maspin Inhibits Cell Migration in the Absence of Protease Inhibitory Activity J. Biol. Chem., November 27, 2002; 277(49): 46845 - 46848. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Palmieri, J. W. Lee, R. L. Juliano, and F. C. Church Plasminogen Activator Inhibitor-1 and -3 Increase Cell Adhesion and Motility of MDA-MB-435 Breast Cancer Cells J. Biol. Chem., October 18, 2002; 277(43): 40950 - 40957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Wong, C. Song, M. M. Grimes, W. Fu, M. W. Dewhirst, R. J. Muschel, and A.-B. Al-Mehdi Intravascular Location of Breast Cancer Cells after Spontaneous Metastasis to the Lung Am. J. Pathol., September 1, 2002; 161(3): 749 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. M. Salicioni, K. S. Mizelle, E. Loukinova, I. Mikhailenko, D. K. Strickland, and S. L. Gonias The Low Density Lipoprotein Receptor-related Protein Mediates Fibronectin Catabolism and Inhibits Fibronectin Accumulation on Cell Surfaces J. Biol. Chem., May 3, 2002; 277(18): 16160 - 16166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. M. Heiss, E. H. Simon, B. C.M. Beyer, K. U. Gruetzner, A. Tarabichi, R. Babic, F. W. Schildberg, and H. Allgayer Minimal Residual Disease in Gastric Cancer: Evidence of an Independent Prognostic Relevance of Urokinase Receptor Expression by Disseminated Tumor Cells in the Bone Marrow J. Clin. Oncol., April 15, 2002; 20(8): 2005 - 2016. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Jo, K. S. Thomas, A. V. Somlyo, A. P. Somlyo, and S. L. Gonias Cooperativity between the Ras-ERK and Rho-Rho Kinase Pathways in Urokinase-type Plasminogen Activator-stimulated Cell Migration J. Biol. Chem., March 29, 2002; 277(14): 12479 - 12485. [Abstract] [Full Text] [PDF]
|
|
